836 related articles for article (PubMed ID: 33686237)
21. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Galon J; Bruni D
Nat Rev Drug Discov; 2019 Mar; 18(3):197-218. PubMed ID: 30610226
[TBL] [Abstract][Full Text] [Related]
22. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.
Zuazo M; Arasanz H; Bocanegra A; Fernandez G; Chocarro L; Vera R; Kochan G; Escors D
Front Immunol; 2020; 11():586907. PubMed ID: 33329566
[TBL] [Abstract][Full Text] [Related]
23. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
24. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
25. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Wang S; Xie K; Liu T
Front Immunol; 2021; 12():690112. PubMed ID: 34367148
[TBL] [Abstract][Full Text] [Related]
26. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
27. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in aggressive B-cell lymphomas.
Jacobson CA; Armand P
Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
[TBL] [Abstract][Full Text] [Related]
29. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
31. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
[TBL] [Abstract][Full Text] [Related]
32. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
[TBL] [Abstract][Full Text] [Related]
33. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
34. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Biomarkers for Melanoma Immunotherapy.
Twitty CG; Huppert LA; Daud AI
Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy.
Shaaban M; Othman H; Ibrahim T; Ali M; Abdelmoaty M; Abdel-Kawi AR; Mostafa A; El Nakeeb A; Emam H; Refaat A
Curr Cancer Drug Targets; 2020; 20(6):429-460. PubMed ID: 32321404
[TBL] [Abstract][Full Text] [Related]
37. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
38. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Giannone G; Ghisoni E; Genta S; Scotto G; Tuninetti V; Turinetto M; Valabrega G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575899
[TBL] [Abstract][Full Text] [Related]
39. The Complexity of Targeting Chemokines to Promote a Tumor Immune Response.
Strazza M; Mor A
Inflammation; 2020 Aug; 43(4):1201-1208. PubMed ID: 32314127
[TBL] [Abstract][Full Text] [Related]
40. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]